Figure01 (Figure01)
The text contains data related to a study that compares the effectiveness of Atenolol and Losartan Potassium in reducing the risk of a primary endpoint in patients. The text shows a graph displaying the study month against the percentage of patients with the primary endpoint. Additionally, the text mentions an adjusted risk reduction of 13% with a p-value of 0.021.*